Pharmacy online blog

When it comes to Bisphenol A (BPA) exposure from polycarbonate plastic bottles, it’s not whether the container is new or old but the liquid’s temperature that has the most impact on how much BPA is released, according to University of Cincinnati (UC) scientists.

Scott Belcher, PhD, and his team found when the same new and used polycarbonate drinking bottles were exposed to boiling hot water, BPA, an environmental estrogen, was released 55 times more rapidly than before exposure to hot water.

“Previous studies gain shown that if you repeatedly scrub, dish-wash and boil polycarbonate baby bottles, they release BPA. That tells us that BPA can migrate from sundry polycarbonate plastics,” explains Belcher, UC associate professor of pharmacology and cell biophysics and corresponding study first cause. “But we wanted to know if ‘normal’ application caused increased release from event that we all use, and to identify what was the mostly important element of a product that impacts release.”

“Inspired by questions from the climbing community, we went directly to tests based on how consumers use these plastic water bottles and showed that the only big difference in exposure levels revolved around liquid degree of heat: Bottles used for up to nine years released the same amount of BPA as new bottles.”

The UC team reports its findings in the Jan. 30, 2008 issue of the journal Toxicology Letters.

BPA is one of many man-made chemicals classified as endocrine disruptors, which alter the function of the endocrine system by mimicking the role of the body’s natural hormones. Hormones are secreted through endocrine glands and serve different functions throughout the body.

The chemical - which is widely used in products such as reusable water bottles, food can linings, water pipes and dental sealants - has been shown to affect reproduction and brain development in animal studies.

“There is a large body of scientific evidence demonstrating the harmful effects of very small amounts of BPA in laboratory and animal studies, but scanty clinical evidence kindred to humans,” explains Belcher. “There is a very strong suspicion in the scientific community, however, that this chemical has harmful effects on humans.”

Belcher’s team analyzed used polycarbonate water bottles from a local climbing gym and purchased novel bottles of the same brand from an outdoor retail supplier.

All bottles were subjected to seven days of testing designed to simulate normal usage during backpacking, mountaineering and other outdoor adventure activities.

The UC researchers found that the amount of BPA released from new and used polycarbonate intemperate habits bottles was the same - both in general conception and speed of release - into cool or temperate water.

However, drastically higher levels of BPA were released once the bottles were briefly exposed to boiling water.

“Compared to the rate of release from the same bottle, the speed of release was 15 to 55 spells faster,” explains Belcher.

Prior to boiling give water to exposure, the rate of release from individual bottles ranged from 0.2 to 0.8 nanograms per hour. After exposure, rates increased to 8 to 32 nanograms per hour.

Belcher stresses that it is still unclear what level of BPA is disadvantageous to humans. He urges consumers to think about how continually increasing environmental exposures might harm their health.

“BPA is just one of many estrogen-like chemicals people are exposed to, and scientists are placid trying to figure out how these endocrine disruptors - including natural phyto-estrogens from soy that are often considered healthy - collectively impact human health,” he says. “But a growing body of scientific evidence suggests it might be at the cost of your health.”

—————————-
Article adapted by Medical News Today from original press release.
—————————-

UC graduate student Hoa Le and summer undergraduate research fellows Emily Carlson and Jason Chua also participated in this study, which was funded by a National Institute of Environmental Health Sciences grant.

Source: Amanda Harper
University of Cincinnati

zyban
Zyloprim
Zyprexa
Zyrtec

The continuous fable of complex, three-dimensional nanoscale structures and the ability to grow individual nanowires of unlimited length are now in posse with a process developed by researchers at the University of Illinois.

Based on the rapid evaporation of solvent from simple “inks,” the process has been used to fabricate freestanding nanofibers, stacked arrays of nanofibers and continuously wound spools of nanowires. Potential applications include electronic interconnects, biocompatible scaffolds and nanofluidic networks.

“The process is taste drawing with a fountain pen - the ink comes loudly and quickly dries or ’solidifies,’ ” said Min-Feng Yu, a professor of mechanical science and engineering, and an affiliate of the Beckman Institute. “But, unlike drawing with a well pen, we can draw objects in three dimensions.”

Yu and graduate students Abhijit Suryavanshi and Jie Hu describe the drawing process in a paper accepted for publication in the journal Advanced Materials, and posted on its Web site.

To use the new process, the researchers begin with a reservoir of ink connected to a glass micropipette that has an aperture as trivial as 100 nanometers. The micropipette is brought close to a substrate until a liquid meniscus forms between the two. As the micropipette is then smoothly pulled gone, ink is drawn from the reservoir. Within the tiny meniscus, the solute nucleates and precipitates as the solvent in a short time evaporates.

So far, the scientists have fabricated freestanding nanofibers approximately 25 nanometers in distance through the centre and 20 microns long, and straight nanofibers approximately 100 nanometers in diameter and 16 millimeters long (limited only through the travel range of the device that moves the micropipette).

To trace out longer nanowires, the researchers developed a precision spinning step that simultaneously draws and winds a nanofiber on a spool that is millimeters in diameter. Using this technique, Yu and his students irritate a coil of microfiber. The microfiber was approximately 850 nanometers in diameter and 40 centimeters long.

To further demonstrate the versatility of the drawing process, for which the U. of I. has applied for a patent, the researchers drew nanofibers out of compliment, out of potassium hydroxide (a major industrial chemical) and out of densely packed quantum dots. While the nanofibers are currently fabricated from water-based inks, the process is readily extendable to inks made with volatile organic solvents, Yu reported.

“Our procedure offers an economically viable alternative for the direct-write manufacture of nanofibers made from many materials,” Yu said. “In etc., the process can be used to integrate nanoscale and microscale components.”

—————————-
Article adapted by Medical News Today from original press release.
—————————-

The Grainger Foundation, the National Science Foundation and the Office of Naval Research provided funding. Part of the work was carried out in the university’s Center for Microanalysis of Materials, which is partly supported by the U.S. Department of Energy.

Source: James E. Kloeppel
University of Illinois at Urbana-Champaign

zyban
Zyloprim
Zyprexa
Zyrtec

The recent finding that the risk of developing ovarian cancer declines the longer a woman takes oral contraceptives is “virtue celebrating, in some measure because health claims about the pill are often much harder to parse,” Slate columnist Amanda Schaffer writes in an opinion piece (Schaffer, Slate, 1/29).

according to the study on ovarian cancer, published Friday in the Lancet, Valerie Beral of the Cancer Research UK Epidemiology Unit at Oxford University and colleagues analyzed data from other than 45 studies conducted in 21 countries worldwide. Women who took oral contraceptives for four years or fewer decreased their risk of ovarian cancer by about 22%, compared by a reduced risk of more than 33% for women who took the pill for five years and a 58% reduced risk for women who took the pill for more than 15 years, according to the study. The protection against the disease remained for more than 30 years after the women stopped using the pill but did decrease over time, the study found (Daily Women’s Health Policy Report, 1/28).

According to Schaffer, the study “seal[ed] the deal” on the benefits of oral contraceptives in preventing ovarian cancer, but the effect of the pill on breast cancer, cardiovascular distemper and sex drive has been a “moving target for medical research.” Some studies have found that verbal contraceptives slightly increase the risk of breast cancer, but the “bottom fill tends toward reassurance” that the pill does not have a extensive effect on breast cancer, Schaffer writes. Studies about the effect of the pill on cardiovascular disease and sex drive “go both ways,” according to Schaffer. Despite “[w]hatever other we don’t know” about oral contraceptives, the finding in the Lancet study that the pill has prevented an estimated 200,000 ovarian cancer cancers and 100,000 deaths from the disease is “decisively good intelligence,” she writes (Slate, 1/29).

Reprinted by species permission from http://www.nationalpartnership.org. You can view the entire Daily Women’s Health Policy Report, search the archives, or prognostic up for email delivery here. The Daily Women’s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2007 The Advisory Board Company. All rights reserved.

zyban
Zyloprim
Zyprexa
Zyrtec

Emerging subtypes of influenza A virus clutch the potential to initiate a world remote epidemic in the next small in number years, according to World Health Organization officials. However, not quite all type A influenza viral strains have become resistant to amantadine and rimantadine, two drugs that make up one of only two classes used to treat the flu.

Researchers at the University of Pennsylvania School of Medicine have now provided a new strategy for insidious drugs that target the resistant viral strains by solving the three-dimensional arrangement of a viral protein called the M2 proton channel. This protein is the molecular receptor as being these drugs. This study is published in the Jan. 31 issue of the journal Nature.

The M2 protein is located in the viral wrapper, forming a long, narrow channel that allows the flow of protons into the viral interior, an essential step for infection. Amantadine sits in this duct and blocks the flow of protons, thus halting infection. In non-resistant viruses, amantadine acts like a cork lodged deep in the channel.

“We apprehend that resistance to amantadine is caused by a mutation in the poison M2 protein, but we did not know for what reason this mutation caused resistance,” explains senior author William F. DeGrado, PhD, Professor of Biochemistry and Biophysics. “Now we do the mutation changes the shape of the channel so amantadine can no longer do its job.”

The structure revealed that there is a pocket in the channel next to the location where amantadine fits that is conserved in all influenza A viruses. This newly discovered room could be the target for new drugs. “Inhibitors that target this cavity adjacent to two highly conserved amino acids in M2 might reclaim the M2-blocking class of drugs so that ongoing endemic outbreaks and future pandemics of this deadly virus might be prevented and treated,” says DeGrado.

“The crystal structures of influenza M2 with and without the anti-influenza drug help us understand the molecular basis of drug resistance, which is a serious problem in treating the flu,” said Jean Chin, PhD, who oversees grants on membrane proteins at the National Institute of General Medical Sciences, which in part funded this research. “The findings will inspire scientists working to design the next generation of antivirals.”

The M2 protein was crystallized so that its structure could be examined under different conditions. This allowed the Penn research team, which included Amanda Stouffer, Rudresh Acharya, David Salom, Cinque Soto, Luigi Di Costanzo, Steven Stayrook, Vikas Nanda, and Anna Levine, to determine the structure of the crystallized protein using a technique called x-ray crystallography.

The stainless protein crystal was bombarded with x-rays so that the position of each atom in relation to its neighboring atoms in the crystal would show up as an rich garments. of black spots. From the pattern of thousands of spots, the structure of the protein be able to be graphically visualized using computer imaging technology.

The next gait is to design new compounds that quid the M2 channel by fitting into the newly discovered larger cavity. The Penn examination group is currently engaged in these studies.

This study was supported by the National Institute of General Medical Studies, the Kimberly and Margaret DeLape Fellowship, the University of Pennsylvania’s MRSEC program, and the National Science Foundation.

Valentina Tereshko of the University of Chicago also contributed to this study.

PENN Medicine is a $3.5 billion endeavor dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System.

Penn’s School of Medicine is currently ranked #3 in the nation in U.S. News & World Report’s survey of top research-oriented medical schools; and, according to most recent facts from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the race’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation’s first hospital; and Penn Presbyterian Medical Center a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

University of Pennsylvania School of Medicine
3600 Market St., Ste 240
Philadelphia, PA 19104
United States
http://www.med.upenn.edu

zyban
Zyloprim
Zyprexa
Zyrtec

The International Myeloma Foundation (IMF) - supporting research and providing education, defence and prop for myeloma patients, families, researchers and physicians - said the positive opinion from the European Medicines Agency (EMEA) could clear the way for a new treatment regulation of diet in Europe. The decision recommends approval of Thalidomide Pharmion® in combination with melphalan and prednisone for newly diagnosed patients from beginning to end 65.

“Thalidomide is the first of what are called the Novel Therapies that - along with VELCADE® and REVLIMID® - have changed the outlook in quest of myeloma patients,” said Susie Novis, president and co-founder of the IMF. “Thalidomide is available in the United States, Australia, New Zealand and elsewhere now, and we would like totally patients to have safe access to its demonstrated benefits.”

The combination of melphalan and prednisone (MP) was once the standard of superintendence on the side of myeloma in Europe, but recent studies have shown the combination is greatly improved by the addition of the Novel Therapies: This positive opinion for thalidomide MP is based on a multi-center clinical trial showing average survival of more than 4 years, a year and a half more than MP without thalidomide. Studies have also shown improved response adding VELCADE to MP and adding REVLIMID to MP.

The recommendation sets the stage for the go of thalidomide to Europe with safe distribution for an important indication. Thalidomide, developed as THALOMID® from the Celgene Corporation, was approved for patients in the United States in 2006. Although once associated with an epidemic of birth defects when prescribed for with child women, a proprietary risk management system in the United States has seen more than 100-thousand prescriptions without a single birth defect, demonstrating the drug can be used safely.

German hematologist Ralph Naumann, of the University Clinic in Dresden, Germany prescribes thalidomide for his patients even though he personally has qualified the effects of thalidomide since his own mother took it when she was pregnant. He has stated: “Thalidomide is not a baneful drug, it’s just a physic that was badly used, and for the many myeloma patients today who are benefiting from thalidomide, that’s a crucial distinction.”

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white cells and stem cells. It affects any estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing in song and in increasingly younger people. There is no cure, but by using therapies in combination and in sequence doctors are moving myeloma toward decorous a chronic ailment.

The positive recommendation could lead to marketing authorization for thalidomide-melphalan-prednisone in the EU within two to three months.

About The International Myeloma Foundation

The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 165,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses on four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 100 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank on a Cure®, a unique gene bank to advance myeloma research. The IMF can be reached at +1818-487-7455.

International Myeloma Foundation

zyban
Zyloprim
Zyprexa
Zyrtec

Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, disclosed that it has filed a provisional patent submission entitled, “Method and Apparatus for Increasing Contaminant Clearance Rates during Extracorporeal Fluid Treatment,” with the U.S. Patent and Trademark Office (USPTO). The patent describes technical improvements to the Aethlon Hemopurifier® that increase the rate of capture of undesirable blood contaminants including viruses, toxins, and immunosuppressive particles associated with cancer.

“Our research team has improved the capability of our Hemopurifier® to remove contaminants from the blood,” stated James A. Joyce, Chairman and CEO of Aethlon Medical. “The related patent submission reflects an ongoing strategy to shield our developments and further increase the breadth of our of the understanding property estate.”

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device designed to treat infectious disease. The Hemopurifier® provides real-time therapeutic filtration of infectious viruses, toxins, and immunosuppressive particles, and is positioned to address the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. The device also holds promise in cancer care, as research studies have verified the capability of the Hemopurifier® to rapidly remove immunosuppressive particles that are secreted by tumors. The Hemopurifier® is targeted for exercise a stand-alone therapeutic, and as an adjunct treatment able to improve the clinical benefit of established and candidate therapies.

Pre-clinical studies conducted by the agency of researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier® in capturing pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. Studies are also being conducted to support the use of the Hemopurifier® similar to a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has previously demonstrated safety of the Hemopurifier® in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) allied to advancing the Hemopurifier® as a broad-spectrum treatment countermeasure against category “A” bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier® technology is available online at http://www.aethlonmedical.com.

Certain of the statements herein may have existence forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any time to come results, performance, or achievements expressed or implied by the forward-looking statements. Such in posse risks and uncertainties include, independently of restraint, the Company’s ability to propagate capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the market of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of place of traffic acceptance, contest, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.

Aethlon Medical

zyban
Zyloprim
Zyprexa
Zyrtec

Sculpting a surface sedate of tightly packed nanostructures that resemble tiny nails, University of Wisconsin-Madison engineers and their colleagues from Bell Laboratories have created a material that can repel almost a single one mellifluous.

Add a jolt of electricity, and the liquid upon the surface slips spent the heads of the nanonails and spreads out betwixt their shanks, wetting the outside completely.

The new momentous, which was reported this month in Langmuir, a journal of the American Chemical Society, could declare a verdict use in biomedical applications such as “lab-on-a- chip” technology, the manufacture of self-cleaning surfaces, and could help extend the acting life of batteries as a way to turn them off when not in use.

UW-Madison mechanical engineers Tom Krupenkin and J. Ashley Taylor and their team etched a silicon wafer to create a forest of conductive silicon shanks and non-conducting silicon oxide heads. Intriguingly, the ability of the surface of the structure to repulse water, oil, and solvents rests without ceasing the nanonail geometry.

“It turns out that what’s important is not the chemistry of the surface, but the topography of the surface,” Krupenkin explains, noting that the overhang of the nail head is what gives his novel surface its dual personality.

A surface of posts, he notes, creates a platform in the way that rough at the nanoscale that “liquid only touches the surface at the extreme ends of the posts. It’s almost like sitting on a layer of air.”

—————————-
Article adapted by Medical News Today from original press receipt in full.
—————————-

Source: Tom Krupenkin
University of Wisconsin-Madison

zyban
Zyloprim
Zyprexa
Zyrtec

Using mice as models, researchers at the Max Planck Institute for Evolutionary Anthropology traced some of the differences between humans and chimpanzees to differences in our diet. The findings appear in the January 30 issue of PLoS ONE.

Humans consume a distinct diet compared to other apes. Not only do we consume much more meat and fat, but we also cook our food. It has been hypothesized that adopting these dietary patterns played a key role during human ascent from simplicity to complexity. However, to date, the influence of diet on the physiological and genetic differences between humans and other apes has not been widely examined.

By feeding laboratory mice different human and chimp diets over a mere two week period, researchers at the Max-Planck-Institute toward Evolutionary Anthropology in Leipzig, Germany, were able to reconstruct some of the physiological and genetic differences observed between humans and chimpanzees.

The researchers fed laboratory mice one of three diets: a raw fruit and vegetable diet fed to chimpanzees in zoos, a human diet consisting of food served at the Institute cafeteria or a pure fast food menu from the local McDonald’s™ (the latter caused the mice to significantly enlist weight). The chimpanzee diet was clearly distinct from the two human diets in its effect on the liver - thousands of differences were observed in the levels at which genes were expressed in the mouse livers. No such differences were observed in the mouse brains. A weighty fraction of the genes that changed in the mouse livers, had previously been observed as different betwixt humans and chimpanzees. This indicates that the differences observed in these particular genes might be caused by the difference in human and chimpanzee diets.

Furthermore, the diet-related genes also appear to have evolved faster than other genes - protein and promoter sequences of these genes changed faster than expected, possibly because of adaptation to new diets.

—————————-
Article adapted by Medical News Today from source press release.
—————————-

Contact:
Mehmet Somel
Svante Pnnbo
Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany

Citation: Somel M, Creely H, Franz H, Mueller U, Lachmann M, et al (2008) Human and Chimpanzee Gene Expression Differences Replicated in Mice Fed Different Diets. PLoS ONE 3(1): e1504. doi:10.1371/journal.pone.0001504

Click here to witness the published article online.

Disclaimer

The following press set free refers to an upcoming article in PLoS ONE. The release has been provided by the article authors and/or their institutions. Any opinions expressed in this are the personal views of the contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of so information.

Source: Mehmet Somel
Public Library of Science

zyban
Zyloprim
Zyprexa
Zyrtec

In young children, psychostimulants relieve symptoms of Attention Deficit Disorder, yet in adolescents and adults, those same medications can cause euphoria and are often abused.

What is behind these differing drug responses?

Temple University scientists have identified a potential molecular mechanism, the neurotrophin system comprised of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, as the cause of old age differences in stimulant response. Their tools and materials offer in the current issue of the Journal of Neuroscience.

“Our findings suggest that the rapidly developing young brain is able to adapt and screen itself against the rewarding effects of stimulants due to the input of the TrkB system,” said Ellen Unterwald, PhD, lead investigator and professor of pharmacology at Temple University’s School of Medicine and Center for Substance Abuse Research.

Most preclinical studies have found that susceptibility to the addictive properties of stimulants is age-dependent. This is the leading study to link the TrkB neurotrophin order to those age-specific responses. The hope is that BDNF/TrkB might someday be used as a target for the development of newly come treatments despite childhood neuropsychiatric disorders or addiction.

—————————-
Article adapted by Medical News Today from original press release.
—————————-

Unterwald and her research team specialize in the effects of drug use, abuse and withdrawal and are currently investigating neurobiological mechanisms involved in drug addiction.

Other authors steady this study are Michelle Niculescu,1 Shane A. Perrine,1 Jonathan S. Miller,1 Michelle E. Ehrlich,2 1Deparment of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, 2Farber Institute because of Neurosciences and Department of Neurology, Thomas Jefferson University College of Medicine, and 3Laboratory of the Biology of Addictive Diseases, The Rockefeller University.

The author wishes to acknowledge the input of her collaborator on this project, Michelle Ehrlich, MD, currently at Mt. Sinai School of Medicine.

This work was supported in part by grants from the National Institutes of Health.

Source: Eryn Jelesiewicz
Temple University

zyban
Zyloprim
Zyprexa
Zyrtec

One in three American women suffers from some mould of cardiovascular disease. And worse yet, approximately one woman dies of heart indisposition every minute. To commemorate National Heart Month, Rite Aid Corporation (NYSE:RAD), through partnerships with fitness guru Billy Blanks® and the American centre Association’s Go Red for Women movement, will offer customers the chance to get heart healthy in a number of ways this February and March.

Working with Billy Blanks, Tae Bo creator, actor, author and humanitarian, the Rite Aid drugstore chain is offering exclusive heart-healthy tips and knowledge of facts. The information includes a set of Amped Moves developed by Billy Blanks himself just for Rite Aid customers. Performing these cardio exercises is the perfect way for customers of any fitness level, age and ability, to take a positive degree attached the road to better health. Customers can visit any Rite Aid store nationwide to pick up the free materials, and start leading healthier lives.

The free comprehensive Rite Aid Heart Guide provides information on detection and prevention of heart disease. It also offers helpful advice on kernel risks, the signs of a heart attack, and helpful products to aide heart health, among other things. “Rite Aid pharmacists and associates are committed to providing the everyday products and services to help valued customers lead healthier lives,” reported John Learish, Rite Aid’s senior executive vice president of marketing. “Couple our Heart Guide with the Billy Blanks Amped Moves workout, and customers will be on their way to battling heart ailment.”

Customers can also have capacity for a Billy Blanks cookbook with heart smart recipes if they purchase $30 desert of select items.

Rite Aid is also giving customers the chance to purchase a “Red Dress” for $1 at any location nationwide. All proceeds from the “Red Dress” sales will good the Go Red for Women emotion of the American Heart Association.

Rite Aid customers aren’t the only ones encouraged to take part in the heart healthy campaign - Rite Aid associates are getting in put on the action, too. On Friday, February 1, associates across the country will wear red to participate in the AHA’s National Go Red for Women Day.

Rite Aid’s focus on heart health is part of its yearlong commitment to patient health and wellness. Each year Rite Aid offers free information, answers and guidance on health and wellness topics including allergy awareness, skin care, pain management, diabetes and heart health.

Rite Aid Corporation is one of the nation’s leading drugstore chains with more than 5,000 stores in 31 states and the District of Columbia. Information about Rite Aid, including incorporated background and press releases, is available through the company’s website at http://www.riteaid.com/.

Since 2004, Go Red toward Women has captured the energy, passion and intelligence of women to work collectively to sneer out heart disease - the No. 1 killer of women. We want millions of women across America to take heart disease personally. Using the platform “Love Your Heart,” Go Red for Women engages women and the men who love them to embrace the cause. Healthcare providers, celebrities and politicians also elevate the cause and spread the word about women and heart disease.

http://www.GoRedForWomen.org

zyban
Zyloprim
Zyprexa
Zyrtec